Pathology Core

$342,427P50FY2016CANIH

Massachusetts General Hospital, Boston MA

Investigators

Linked publications & trials

Paper 39677480 Paper 39499201 Paper 39386427 Paper 39315894 Paper 39082676 Paper 38991060 Paper 38984985 Paper 38839962 Paper 38798554 Paper 38760585 Paper 38718141 Paper 38645003 Paper 38579724 Paper 38503282 Paper 38446044 Paper 38301244 Paper 38221978 Paper 37986801 Paper 37978951 Paper 37791581 Paper 37652004 Paper 37609311 Paper 37609137 Paper 37516774 Paper 37425854 Paper 37399061 Paper 37138086 Paper 37059069 Paper 37024595 Paper 36963492 Paper 36917953 Paper 36853662 Paper 36847506 Paper 36780194 Paper 36694348 Paper 36693322 Paper 36652537 Paper 36617262 Paper 36471067 Paper 36288726 Paper 35985343 Paper 35985342 Paper 35957525 Paper 35715666 Paper 35641483 Paper 35604410 Paper 35589737 Paper 35304604 Paper 35304445 Paper 35292783 Paper 35259916 Paper 35239963 Paper 34951647 Paper 34651608 Paper 34610309 Paper 34609036 Paper 34570454 Paper 34493595 Paper 34470822 Paper 34389641 Paper 34261799 Paper 34102393 Paper 34087162 Paper 34040258 Paper 33997789 Paper 33737485 Paper 33592174 Paper 33532737 Paper 33431926 Paper 33239433 Paper 33223023 Paper 33140540 Paper 33130879 Paper 33112994 Paper 33025139 Paper 32997991 Paper 32946145 Paper 32929121 Paper 32927482 Paper 32710757 Paper 32606138 Paper 32576627 Paper 32381657 Paper 32350978 Paper 32322066 Paper 32236425 Paper 32064507 Paper 31909698 Paper 31900275 Paper 31581174 Paper 31563982 Paper 31427603 Paper 30975663 Paper 30948807 Paper 30799286 Paper 30742782 Paper 30715997 Paper 30683719 Paper 30668823 Paper 30659155

Abstract

The overall goal of this SPORE application is to develop more effective targeted molecular therapies and biomarkers for glioblastoma. The four proposed projects focus on 1) Overcoming resistance to VEGF inhibition by targeting Angiopoietin-2; 2) Inhibiting the phosphatidylinositol 3-kinase (PI3 kinase) pathway; 3) designing novel strategies for imaging and targeting IDH mutant gliomas; and 4) Increasing the radiosensitivity of glioblastomas by inhibiting the bHLH transcription factor Olig2. One ofthe innovative themes of this SPORE proposal is that biospecimens collected by the Pathology Core will be comprehensively moiecuiariy profiled using multiplexed technologies so projects may effectively evaluate the interaction of targeted therapies and their targets. The Pathology Core will support the goals of the SPORE by providing expert neuropathologic review, biospecimen banking and clinical trial support. In addition, the Pathology Core will be a centralized resource for clinically and moiecuiariy annotated glioblastoma tissues and primary glioblastoma cell cultures that will be essential to the success of the proposed projects. By centralizing these activities, the Pathology Core will ensure the safe and effective use of finite glioblastoma tissue resources without limiting the scope of the translational research planned in this proposal. The SPORE support, combined with significant institutional support for these goals, will ensure that over the next 5 years the Pathology Gore will provide the critical research infrastructure required for successful, collaborative translational research ofthe SPORE program.

View original record on NIH RePORTER →